featured
Risk of Systemic Adverse Events Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Ophthalmology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Risk of Systemic Adverse Events Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice
Ophthalmology 2020 Aug 08;[EPub Ahead of Print], MH Maloney, SR Payne, J Herrin, LR Sangaralingham, ND Shah, AJ BarkmeierFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.